Experience our Spectacular Science
At Regeneron, we don't shy away from a scientific challenge because we know nothing is out of bounds. We follow the science to find solutions to insurmountable problems in human health. We question everything. This philosophy is what inspires us to harmonize biology and technology, marrying the best of both to revolutionize research on how we target and treat serious diseases. It's why we created the Regeneron Genetics Center®, home to the largest and most diverse genomic database in the world. It's why we are perfecting novel technologies like CRISPR and gene silencing. And it's why we'll continue to stay on the cutting edge as we build the medicines of tomorrow.
Join us for a series decades in the making.
We explore millions of genetic codes, advance drug discovery through technology, identify powerful genes and triumph against the most challenging diseases.
Follow Regeneron's quest for Spectacular Science.
The time is coming when the most challenging diseases of today will be a footnote in our history.
And we’ll get there because a group of scientists questioned what would be possible by uniting biology and technology.
How could the human body inspire new cures?
How can new treatments be identified, tested, and produced faster?
How can we find more potential paths forward?
Determined to overcome the limitations around us, we built new tools and put the genetic code of humans into a magic mouse.
Now we create new, fully human antibodies that may help treat life-altering illnesses.
And develop antibody treatments at a rapid speed that matches the outbreaks they fight.
The convergence of biology and technology is evolving — new innovations will lead to even more potentially life-changing medicines.
And we’ll find those treatments because Regeneron scientists never stop asking ‘what’s next?’
Creating medicines of the future requires technology that outpaces the diseases we’re chasing.
That’s why Regeneron is building a cutting-edge technological toolkit powered by human genetics and biology.
We started with VelociSuite® to fuel the rapid discovery and development of fully human antibody medicines.
Scientists can now engineer a magic mouse model of human disease, trigger immune responses to produce antibodies suitable for humans, and even create new antibody structures as potential tools in the fight against cancer.
Our world-class manufacturing team then uses unique cell production technologies to scale up new medicines for investigation and impact.
The innovation continues with collaborations that pair our revolutionary thinking with novel technologies to potentially target serious diseases that can’t be addressed with biologics alone.
By growing our toolkit, we are able to make new treatments faster and are following the science to help those who need it most.
Within every human being lies the potential to help cure and prevent disease.
That insight inspired us to build the largest, most diverse genomic database in the world, along with novel tools to help mine the endless possibilities.
Because all it takes is finding one mutated gene, one genetic superpower hidden deep in a person’s DNA to open the door for protecting countless others.
At Regeneron Genetics Center®, we’ve invented new robots and processes, even incorporated artificial intelligence and machine learning, to quickly sequence the genes of millions of people, analyze the data and find ways a person’s genes can protect or expose them to disease.
When a promising mutation is found, we use our core technologies to validate the target and explore safety. Then, a potential new treatment is born.
We’re diving deep into the genetic code to find the superpowers sparking the potential of genetics medicine.
Once the stuff of fantasy, editing human DNA to combat genetic diseases is now a medical reality with the potential to replace burdensome therapies with one-time treatments.
Imagine being able to edit DNA like computer code. Precisely removing bits that provide faulty instructions, or adding in new code to help things run smoothly gives the body’s protein making machinery a fully functional set of instructions— hopefully prompting health and healing.
We’re building in-house capabilities and collaborating with fellow pioneers putting CRISPR to work inside the human body to help efficiently take on genetic disorders.
We’ve developed “knock-out” technology to potentially target rare diseases and “knock-in” technology that seeks to provide a functional copy of broken genes that cause life-long conditions.
Gene editing gives us the potential to address serious illnesses in brand new ways, and renewed hope for a healthier future.
Because sci-fi is only fiction until it’s science.
Technology for now
and the future
Technology is foundational to our work inventing new medicines. By combining the deep scientific expertise of our team with our proprietary VelociSuite® technologies, as well as other complementary technologies, we accelerate the way medicines are traditionally discovered and developed. Building on our portfolio of homegrown medicines, we continue to evolve our approach to antibody discovery and development, while also exploring new methods of addressing human disease, like gene editing.
0ur VelociSuite® technology platform
Our industry-leading capabilities for antibody target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional process. VelociSuite includes some of the most valuable biotechnologies ever created and has enabled the development of approximately one in five of all original, FDA-approved or authorized fully human monoclonal antibodies currently on the market.
These tools ultimately allow us to help more patients around the world, faster. Regeneron also provides the VelociSuite technologies to its collaborators as vital services to assist in the drug discovery and development process.
VelociGene facilitates the rapid, automated and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of these modifications. This enables unprecedented speed and capacity for the validation of therapeutic targets and the creation of animal models of human disease – critical first steps in process of developing new medicines.
VelocImmune is our unique technology for producing optimized fully human monoclonal antibodies. It utilizes a proprietary mouse platform engineered with a genetically humanized immune system. VelocImmune creates a multitude of antibody drug candidates efficiently and directly from immunized mice, overcoming limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential negative immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.
VelocImmune stems from Chief Scientific Officer George D. Yancopoulos’ work as a graduate student, when he was the first to envision making such a genetically humanized mouse.
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. This allows us to select the best candidates and prepare them for initial manufacturing in record time – going from mouse immunization to production cell line bioreactor harvest within eight months.
VelociMouse is a breakthrough technology that enables the immediate generation of genetically altered mice directly from modified embryonic stem cells, thereby avoiding the need to breed multiple generations of mice. This technology has dramatically shortened the time needed to engineer genetically modified mice, while at the same time reducing costs and improving precision.
VelociT is our service for producing genetic sequences for our partners and collaborators to assist in the creation of fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens.
VelociHum is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models. Through genetic humanizations, VelociHum mice have been optimized to allow for better development of human immune cells in vivo, as well as to allow for engraftment of primary patient-derived tumors that do not take in other commercially available mice.
Veloci-Bi allows for the generation of full-length bispecific antibodies similar to native antibodies that are amenable to being made through standard antibody manufacturing techniques and are likely to have favorable, antibody-like pharmacokinetic properties.
Advancing our technologies
We continually push the bounds of science to discover new ways to make a positive impact on human health – and this also applies to our technologies. Just as we have continued to develop the VelociSuite platform over decades, like with the addition of Veloci-Bi, we are also pursuing other innovative ways to address diseases, including with genetic medicine approaches.
Applying our tech to discover DNA-based vaccines
The Molecular Vaccine Technology Center was launched in 2021 to provide internal support to our researchers who are developing molecular vaccines for oncology, infectious disease and immune inflammation approaches. The Molecular Vaccine Tech Center will establish in-house plasmid DNA and mRNA vaccine platforms to deliver antigens either to dendritic cells or directly to T cells for activation.
Our teams can fast-track vaccine projects by screening hundreds of vaccine candidates in combination with different DNA, mRNA and protein delivery approaches in order to select leads for clinical investigation.
In addition, at the end of 2021, Regeneron entered into a multi-year collaboration agreement with Nykode Therapeutics (formerly Vaccibody) to develop innovative vaccines against cancer and infectious diseases. Nykode has developed a plasmid DNA-launched vaccine platform that efficiently delivers antigens to help kickstart an immune response. The protein product that is launched by the plasmid DNA, the so-called “Vaccibody,” contains a series of encoded antigens linked to a targeting domain that promotes delivery to dendritic cells, which initiate an immune response. The platform has already shown robust CD8 T-cell responses in animal models and in patients with cancer.
Bispecific antibody clinical progress thanks to advancing technologies
To solve the human body’s most complex mysteries, we must continually build upon our existing technologies, just as we have done with Veloci-Bi. We developed the platform to overcome common issues seen with other bispecific creation methods, such as undesired immune responses or instability in vivo. By addressing these hurdles, we can create high quality bispecific antibodies at fast speeds.
As our bispecific antibody pipeline matures, we are encouraged by progress to address solid tumors and hematological conditions. Check out our clinical pipeline to see our bispecific antibody candidates.
Regeneron’s deep scientific
expertise across modalities
Our Trap technology was motivated by a dissatisfaction with the specificity and binding affinity of human antibodies that could be developed using the most-advanced antibody technologies at the time. Building on insights into the basic mechanisms of receptor action discovered at Regeneron, our scientists developed a general approach to create high-affinity blockers for many different types of signaling molecules. This novel Regeneron Trap technology creates circulating "decoy receptors" capable of reducing or eliminating the harmful effects of a signaling protein.
Expertise in cell production
Our EESYR®, FASTR® and NICE® technologies and services significantly increase protein-production yields in cell-line development for our research and clinical programs, as well as for our partners:
- EESYR provides site-specific integration into a transcriptional hot spot in the eukaryotic cell genome, resulting in rapid isolation of cells capable of high-level expression of recombinant therapeutic proteins
- FASTR is a quantitative cell-surface display technology that enables the use of flow cytometry to select eukaryotic cells that secrete the highest levels of recombinant therapeutic proteins
- NICE enables the control of the expression of secreted, recombinant therapeutic proteins in eukaryotic cells
Our rapid response to
We are always looking for ways to make the drug discovery process faster and more efficient, especially when help is desperately needed in a short amount of time. To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite technologies in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups in order to advance novel antibody treatments faster than ever. We’ve been proud to apply our homegrown technologies and novel scientific approach to respond to public health challenges like Ebola, Middle Eastern Respiratory Syndrome (MERS) and COVID-19.